Company intelligence / Profile preview

Neuromod Devices

Dublin, Leinster, Irelandtinnitustalk.com ↗

Ownership: Private
Development stage: Other

Overview

Neuromod’s Lenire/mutebutton device has demonstrated safety, efficacy, and patient tolerability through three large-scale clinical trials involving over 600 patients. The results have been published in peer-reviewed journals. The device was awarded CE mark approval in Europe in 2014 and received an FDA De Novo Grant for the treatment of tinnitus in the United States.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyBimodal neuromodulation
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Neuromod Devices.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuromod Devices.

Explore the full profile